Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazarotene/ulobetasol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch Health Companies; Valeant Pharmaceuticals International

    • Most Recent Events

    • 01 Jun 2022 Data from pooled analysis from (NCT02462070; NCT02462122 and NCT02462083) studies published in the Journal of Dermatological Treatment
    • 04 Mar 2020 Systematic review assessing phase II and phase III clinical trial data (NCT02045277, NCT02785172, NCT02462070, NCT02462122 and NCT02462083) pertaining to efficacy and safety of HP/TAZ combinational topical therapy published in the Annals of Pharmacotherapy
    • 25 Apr 2019 According to a Bausch Health Companies media release, the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top